Printer Friendly

Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development.

M2 PHARMA-January 29, 2016-Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development

(C)2016 M2 COMMUNICATIONS

Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) revealed on Thursday the addition of Kimberly J. Manhard as executive vice president of its drug development.

Effective immediately, Manhard will report to the company's chief executive officer, Barry D. Quart, Pharm.D.

Since 2008, Manhard has served as senior vice president of Regulatory Affairs and Development Operations, corporate compliance officer and director at Ardea Biosciences, a wholly-owned subsidiary of AstraZeneca PLC.

Prreviously, Manhard has worked as president of her own consultancy firm, vice president of Regulatory Affairs for Exelixis as well as held multiple regulatory positions at Agouron Pharmaceuticals, a Pfizer Inc company, and Bristol Myers Squibb Company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 29, 2016
Words:134
Previous Article:Kentucky dental surgery recruits three new members to dental team.
Next Article:The Pharmacy Technician Certification Board names new director of Strategic Alliances.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |